Orum Therapeutics (475830) 🔎 In-depth
KOSDAQ · Price as of 2026-08-06 · Updated 2026-08-09
Orum Therapeutics does not sell drugs but is a clinical-stage biotech that develops new-drug candidates, licenses them out to global pharmaceutical companies, and collects upfront payments, milestones and royalties, with its core being TPD² (DAC) technology that loads a protein-degrading drug onto an antibody that binds to cancer cells and delivers it. In years without a deal, revenue falls to effectively near zero, and past examples of value creation include a candidate licensed out to BMS (up to $180 million total) and a platform license/option deal with Vertex (a $15 million upfront and up to $310 million per target). What stands out lately is that BMS and Vertex actually paid upfronts, corroborating the platform's value, and low debt keeps near-term survival risk low; on the other hand, with no product revenue, results swing sharply around deal timing, and uncertainty over clinical success is high, including an adverse-event issue with a lead clinical candidate, so value hinges on pipeline progress and further licensing.
This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.
30-second brief
Pulled directly from the computed values below — not a separately written opinion.
What do the SourceComputedEstimateReading tags mean?
Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.
Core valuation metric
This stock's effective sub-sector is “Biotech (Drug Development & Research)” (Biotech & Pharmaceuticals), a type best read first through qualitative factors such as pipeline value and cash runway rather than earnings multiples.
Drug-discovery biotech firms often have little in the way of earnings or revenue yet, so P/E or sales multiples can't meaningfully capture their value. Instead, it makes more sense to judge them qualitatively — by the clinical stage of the pipeline, licensing and out-licensing progress, and the cash runway that keeps research going.
That said, meaningful revenue has yet to ramp, so pipeline value and cash runway may matter more than this metric.
This note explains how each sector is typically valued and is educational context only, not investment advice.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue fell 99.9% year over year (3-year trend: falling).
- Most recent quarter (Q1 2026) revenue was 100.0% lower than a year earlier.
- ROE is -32.1% (total-net basis). It is below the sector average.
- Operating margin is -219651.4%.
- A sector-metric and in-depth research verdict — see “Valuation vs peers” below for the basis.
Ownership & governance As of 2025-12-31
Largest shareholder Lee Seung-joo 15.96% (individual)
Controlling bloc incl. related parties 16.41%
With the controlling bloc holding 16%, control is maintained but the free float is relatively large.
🔎 In-depth analysis Reading
Orum Therapeutics is not a company that earns money by selling drugs, but a clinical-stage biotech that develops new-drug candidates, licenses them out to global pharmaceutical companies, and receives upfront payments, stage-based milestones and royalties. Its core technology is a DAC (degrader-antibody conjugate) called TPD² (dual-precision targeted protein degradation). In simple terms, it loads 'a small drug that degrades disease-causing proteins' onto an antibody that binds only to cancer cells and delivers it precisely. So far most revenue has come not from product sales but from such licensing deals. The large revenue booked in 2023 was likewise due to one-off deal inflows such as the candidate licensed out to Bristol Myers Squibb (BMS), and in years without a deal revenue falls to effectively near zero.
The latest close is ₩58,500 and the market capitalization is ₩1.3 trillion. The price sits above its 20-day moving average (₩46,782) and above its 60-day moving average (₩57,968). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 59.3, a neutral level. The one-month change is +15.2%, the three-month change is -34.3%, and the position relative to the 52-week high is -59.3%. Relative strength versus the KOSDAQ is 83 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 83% of all stocks. Over the past three months it outpaced the index by 2.4%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
This company's finances should not be measured by the yardstick of a 'profit-making firm.' Revenue in 2025 was effectively zero (₩23.56 million), down 99.9% year on year, but this is not because the business broke down; it is because there was no new licensing upfront that year. With an operating loss of ₩51.8 billion and a net loss of ₩42.0 billion, it is the typical picture of a development-stage company that keeps spending on R&D. ROE (how much is earned on equity in a year) is -32.1%, in a loss state. The P/E ratio (how many years of earnings the price represents) cannot be computed at all because earnings are negative. The P/B (how many times net assets the price represents) is 10.63x, which looks high, but a biotech's book equity barely reflects the future value of its pipeline still under development, so it cannot be called expensive on this multiple alone. The financial structure itself is on the solid side. The debt ratio (debt against equity) is a low 29.4%, the current ratio (cash-like assets against debt due within a year) is a very high 860.9%, and net debt is around ₩21.4 billion, so there is no great immediate funding pressure. In short, it is 'loss-making but with room still in the coffers.'
The 'growth rates' of revenue and profit have little meaning in judging this company. Revenue falling from ₩135.4 billion in 2023 to ₩20.9 billion in 2024 to near zero in 2025 is not a slowdown in growth; it is merely the difference between years with a licensing deal and years without one. What should really be watched is pipeline progress. The lead candidate ORM-6151 (CD33-targeting blood cancer) was licensed out to BMS. ORM-5029 (HER2-targeting solid tumors) went through Phase 1, but development was checked by a serious adverse-event issue. On the other hand, the new candidate ORM-1153 (CD123-targeting acute myeloid leukemia) disclosed preclinical data at the 2026 American Association for Cancer Research (AACR) meeting and moved up to a clinical-entry preparation stage. ORM-1023 is following behind. The revenue recovery ahead depends on these new candidates entering the clinic and on securing further licensing deals.
Most recent filings are routine items related to shareholdings and management. On June 10, 2026 the company held an investor briefing (IR) to explain the pipeline's progress to the market. In March-April there were stock-option exercises, major-shareholder and officer shareholding changes, regular shareholders' meeting results, and outside-director appointments. What substantively moves company value is not such routine filings but licensing and clinical events. The past candidate licensed out to BMS (up to $180 million total) and the multi-target TPD² platform license/option deal with Vertex (a $15 million upfront, up to $310 million per target) were the representative examples of value creation.
This is a textbook platform biotech with clear strengths and weaknesses. The strength is validation of its proprietary DAC technology. The fact that global pharmaceutical companies such as BMS and Vertex actually paid upfronts corroborates the platform's commercial value. The financial structure, with little debt and cash to spare, keeps near-term survival risk on the low side. The cautions are just as clear. With no product revenue yet, results swing sharply with the timing of deal inflows. Given that the lead clinical candidate had an adverse-event issue, uncertainty over clinical success is high. In the end this stock's value hinges not on 'profit' but on the events of 'pipeline progress and further licensing.' If new candidates enter the clinic and licensing proceeds smoothly it is strong; if clinical delays or deal gaps drag on it is weak. Judged by the ordinary yardsticks of a normal company, such as the P/E or revenue growth rate, the picture is easy to miss.
🔎 Valuation vs peers Inconclusive
Domestic antibody-conjugate (ADC/DAC) and platform biotechs that develop and license out new-drug candidates on their own platform before product revenue.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| LigaChem Biosciences | 0.00x | 8.87x | -18.04% |
| Alteogen | 111.02x | 31.22x | 25.80% |
This company's earnings are negative, so value cannot be measured by the P/E. Revenue also swings year to year depending on whether there is a licensing deal, so the P/S has weak meaning too. Among peers in the same position, LigaChem Biosciences, a leading domestic ADC platform firm, is also loss-making with no P/E and trades at a P/B of 10.42x. Alteogen is a case where the platform-license approach reached a successful track and was re-valued after turning profitable, at a P/B of 42x and P/E of 133x. Orum Therapeutics' P/B of 8.73x is on the low side among the peers, but this reflects that it is at an early-to-mid development stage where commercialization and large licensing track records have not yet accumulated as they have at Alteogen. In the end, whether it is undervalued or overvalued depends on future pipeline progress and whether further licensing materializes, so on current metrics alone it is more accurate to hold judgment.
Price history Close · MA20 · MA60
The latest close is ₩58,500 and the market capitalization is ₩1.3 trillion. The price sits above its 20-day moving average (₩46,782) and above its 60-day moving average (₩57,968). It holds above both its short- and medium-term moving averages, so the trend looks healthy. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 59.3, a neutral level. The one-month change is +15.2%, the three-month change is -34.3%, and the position relative to the 52-week high is -59.3%. Relative strength versus the KOSDAQ is 83 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 83% of all stocks. Over the past three months it outpaced the index by 2.4%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M +2.35% / 6M -24.24% / 12M +166.57%
Key metrics Computed vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 10.63x is above the sector median (1.10x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
Return on equity (ROE) is -32.1%, below the sector average (1.0%). The operating margin is -219651.4%. The debt ratio is 161.6%, so the financial structure is moderate.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $95.1M | $14.7M | $16,554 | -99.89% ↓ slower |
| Operating profit | $67.2M | -$5.9M | -$36.4M | — |
| Net profit | $47.9M | -$4.0M | -$29.5M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $95.1M | $14.7M | $16,554 |
| Operating profit | — | — | $67.2M | -$5.9M | -$36.4M |
| Net profit | — | — | $47.9M | -$4.0M | -$29.5M |
| Revenue CAGR | 2-yr avg -98.68% | ||||
Revenue fell 99.9% year over year (2023 ₩135.4 billion → 2024 ₩20.9 billion → 2025 ₩23,564,233), and the three-year trend is 'falling'. The rate of decline widened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 3 years on record, revenue compound annual growth (CAGR) is -98.7%. The two-year revenue CAGR is -98.7%. In the most recent quarter (Q1 2026), revenue was 100.0% lower than the same period a year earlier.
Latest quarterly results Source Q1 2026 · vs year-ago
Technical indicators Computed
What stands out
- —
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- Revenue fell 99.9% year over year (3-year trend: falling).
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-06-10IRInvestor briefing (IR) held, explaining pipeline and business progress to the marketBears less on short-term price direction than on market confidence in the pipeline-progress and licensing roadmap. Source
- 2026-04-01FilingStock-option exercise, the new-share procedure from employee stock-option exerciseA minor factor increasing the share count, but the impact on the company's intrinsic value is limited. Source
- 2026-03-27FilingRegular shareholders' meeting results, handling routine agenda such as financial-statement approval and director appointmentsConfirmatory in character regarding governance and management continuity; the short-term earnings impact is neutral. Source
- 2026-05-15EarningsQ1 2026 quarterly report, a net loss of ₩15.28 billion as R&D continued with no product revenueThe expected continuing loss of a development-stage company; the watch point is pipeline progress rather than the bottom line. Source
Figure cross-check computed ↔ external
Recent filings Source
- 2026-06-10Disclosure
- 2026-06-09OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-09OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-09OwnershipOwnership-change filing
- 2026-05-15PeriodicQuarterly report
- 2026-04-08Amended filing
- 2026-04-01Disclosure
- 2026-03-31OwnershipOwnership-change filing
- 2026-03-31OwnershipOfficers'/major-shareholders' holdings report
- 2026-03-30Disclosure
- 2026-03-27Shareholders' meeting notice
- 2026-03-27Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.